Evidence map›Paper›PMID 31686910›Full record

ArticleCancer management and research2019

Antibiotic therapy augments the efficacy of gemcitabine-containing regimens for advanced cancer: a retrospective study.

Hiroo Imai, Ken Saijo, Keigo Komine, Yasufumi Otsuki, Kota Ohuchi, Yuko Sato, Akira Okita, Masahiro Takahashi, Shin Takahashi, Hidekazu Shirota and 2 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer management and research, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed
2.6field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 28 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Article
  6. Review
  7. Article
  8. Review
  9. Article
  10. Review
  11. Article
  12. Review
  13. Article
  14. Review
  15. Article
  16. Review
  17. Observational
  18. Article
  19. Review
  20. Gut microbes
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 2 institutions in 1 country.

Hiroo ImaiDepartment of Medical Oncology, Tohoku University Hospital, Sendai, Japan.
Ken SaijoDepartment of Medical Oncology, Tohoku University Hospital, Sendai, Japan.
Keigo KomineDepartment of Medical Oncology, Tohoku University Hospital, Sendai, Japan.
Yasufumi OtsukiDepartment of Clinical Oncology, Institute of Developing, Aging and Cancer, Tohoku University, Sendai, Japan.
Kota OhuchiDepartment of Medical Oncology, Tohoku University Hospital, Sendai, Japan.
Yuko SatoDepartment of Medical Oncology, Tohoku University Hospital, Sendai, Japan.
Akira OkitaDepartment of Clinical Oncology, Institute of Developing, Aging and Cancer, Tohoku University, Sendai, Japan.
Masahiro TakahashiDepartment of Medical Oncology, Tohoku University Hospital, Sendai, Japan.
Shin TakahashiDepartment of Clinical Oncology, Institute of Developing, Aging and Cancer, Tohoku University, Sendai, Japan.
Hidekazu ShirotaDepartment of Medical Oncology, Tohoku University Hospital, Sendai, Japan.
Masanobu TakahashiDepartment of Clinical Oncology, Institute of Developing, Aging and Cancer, Tohoku University, Sendai, Japan.
Chikashi IshiokaDepartment of Clinical Oncology, Institute of Developing, Aging and Cancer, Tohoku University, Sendai, Japan.
Tohoku University Hospital · JPTohoku University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe addition of antibiotics reportedly augments the efficacy of gemcitabine (GEM) in tumor-bearing mice. However, whether this phenomenon is also observed in cancer patients remains unclear. In the present study, we aimed to assess whether antibiotics for treatment or prevention of infection augments treatment efficacies of GEM-containing regimens in patients with any type of cancer.

methodsMedical records of patients diagnosed with cancer histopathologically and treated with GEM-containing regimens (n=169) were retrospectively reviewed. Patients were assigned into two groups: antibiotics-untreated group (patients who were treated with GEM-containing regimens but without antibiotics) and antibiotics-treated group (patients who were treated with GEM-containing regimens plus antibiotics). Response rates, progression-free survival (PFS) time, and overall survival (OS) time were analyzed for each group.

resultsThe response rates of the antibiotics-untreated and antibiotics-treated groups with GEM-containing regimens were 15.1% and 27.6%, respectively. The median PFS times of the antibiotics-untreated and antibiotics-treated groups were 2.5 (95% CI: 1.86-3.73) and 4.9 (95% CI: 3.47-6.0) months, respectively. The median OS times of the antibiotics-untreated and antibiotics-treated groups were 7.53 (95% CI: 5.63-9.57) months and 13.83 (95% CI: 10.83-16.43) months, respectively.

conclusionThe addition of antibiotics augments the treatment efficacies of GEM-containing regimens, and it may be a potential therapeutic option to improve treatment efficacies of GEM-containing regimens in patients with advanced cancer.

Indexed as

antibioticsbacteriagemcitabinemultivariate analysisunivariate analysis

Identifiers

PMID31686910
PMCPMC6709792
OpenAlexW2969372641

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.